-
4-21-11 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com
Thursday, April 21, 2011 - 12:27pm | 3937Chuck Mikolajczak. Reuters Wall Street edges up on profits but data caps gains NEW YORK (Reuters) – U.S. stocks rose on Thursday in a holiday-shortened week on earnings and outlooks, but the gains were tempered on signs of regional economic weakness. Apple Inc (NasdaqGS:AAPL) climbed 2.6 percent to...
-
Biotech/Pharma Investor Spotlight; Profile for BioSante Pharmaceuticals and its Lead Products, LibiGel® and Bio-T-Gel™
Thursday, April 21, 2011 - 12:02pm | 1206Point Roberts, WA - April 21, 2011 (Investorideas.com Newswire) Investorideas.com, a leader in sector stock research including biotech and pharma stocks, profiles BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and its lead products, LibiGel® (testosterone gel) and Bio-T-Gel. Hi-lights are featured...
-
Perrigo's PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
Thursday, April 21, 2011 - 10:16am | 66Perrigo Company (Nasdaq: PRGO) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision that Mead Johnson (NYSE: MJN) had engaged in false advertising resulting in an injunction prohibiting Mead Johnson from making similar claims and awarding...
-
DepoMed Ticks Higher After Positve Blog Post At SeekingAlpha (DEPO)
Thursday, April 21, 2011 - 9:52am | 24DepoMed (NASDAQ: DEPO) Ticks Higher After Positve Blog Post At SeekingAlpha. http://seekingalpha.com/article/264716-depomed-light-risk-small-pharma-with-huge-potential
-
Cephalon Recommends Shareholders Reject Valeant's Consent Solicitation to Remove Cephalon's Board of Directors
Thursday, April 21, 2011 - 9:51am | 86Cephalon, Inc. (NASDAQ: CEPH) today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission urging shareholders to reject Valeant Pharmaceuticals International Inc.'s (NYSE: VRX) proposals to remove Cephalon's entire Board of Directors and...
-
Pre-market News and Views
Thursday, April 21, 2011 - 9:40am | 505The holiday rally continues again this morning after strong corporate earnings reports by Apple Inc.(NASDAQ: AAPL), and Qualcomm Inc.(NASDAQ: QCOM). The S&P 500 Index e-mini futures(ES-M1) are trading higher by 5.00 points to 1333.00 per contract. Often, before a long holiday weekend the major...
-
UPDATE: Piper Jaffray Color On SLXP Target Increase
Thursday, April 21, 2011 - 8:21am | 141Piper Jaffray, which raised its PT on shares of Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), is providing some color on the stock. “Yesterday, Salix announced that the U.S. Patent and Trademark Office issued three additional patents for Xifaxan (rifaximin),” Piper Jaffray writes. “We believe the...
-
Benzinga's Top Pre-Market NASDAQ Losers (TEVA, SINA, VOD, ISPH)
Thursday, April 21, 2011 - 8:17am | 113Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) dipped 3.80% to $47.30 in the pre-market session. TEVA is scheduled to report its Q1 results on May 11. Sina Corporation (NASDAQ: SINA) fell 3.38% to $138 in the pre-market session. SINA's PEG ratio is 4.65. Vodafone Group Plc (NASDAQ: VOD) moved...
-
Wedbush Reports Solid Results But Fizzling Stocks For Abbott Labs
Thursday, April 21, 2011 - 8:07am | 160According to Wedbush, Abbott Laboratories (NYSE: ABT) solid results gave no boost to the stock. Wedbush said that Abbott Labs beat Q1 expectations, guided Q2 and full year numbers in line, sustained strong growth for its largest product, validated its emerging markets growth model, and outlined an...
-
Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases
Thursday, April 21, 2011 - 8:05am | 82Merck (NYSE: MRK) and Sanofi Pasteur, the vaccines division of sanofi-aventis Group (NYSE: SNY), announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine1. This combination vaccine is...
-
Piper Jaffray Raises PT on Salix Pharmceuticals To $42
Thursday, April 21, 2011 - 6:38am | 27Piper Jaffray has raised the price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $39 to $42 and maintains its Overweight rating.
-
Actient Pharmaceuticals LLC Acquires U.S. Rights to STRIANT (CBRX)
Wednesday, April 20, 2011 - 4:32pm | 93Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into an asset purchase agreement with Actient Pharmaceuticals LLC, a privately-held specialty therapeutics company, for STRIANT^® in the United States. Under this agreement, Columbia has sold STRIANT to Actient for a combination of cash...
-
Growthflation 04-20-2011
Wednesday, April 20, 2011 - 3:26pm | 1036Cusick's Corner RISK ON -- trading in a growthflationary (growth & inflationary atmosphere) market is really on! This market clearly had more pent up demand than expected. The headlines in the last two sessions were what most market watchers thought would bring this rally to its knees but then...
-
Dynavax Initiates First Human Trial in Lupus Program
Wednesday, April 20, 2011 - 12:31pm | 132Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its lupus program. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline (GSK), its partner in a worldwide strategic alliance....
-
Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership (PFE)
Wednesday, April 20, 2011 - 11:27am | 35Shanghai Pharmaceutical and Pfizer Inc. (NYSE: PFE) today announced the signing of a memorandum of understanding for the companies to jointly pursue potential business opportunities in China.